Therapy with canakinumab for gout
https://doi.org/10.14412/1995-4484-2018-41-48
Abstract
A significant part of patients with gout has contraindications to taking nonsteroidal anti-inflammatory drugs, colchicine and glucocorticoids. Such therapy is often ineffective, particularly in patients with the severe tophaceous gout what hampers treatment of acute arthritis attack assuming the need for other methods of therapy. During the last years several medications have been introduced the mechanism of anti-inflammatory action of which is associated with inhibition of interleukin 1 (IL1) playing a key role in the development of acute gouty arthritis. To date, the most well-studied and the only registered drug for relief of acute arthritis attack is canakinumab, recommended for use in situations where other therapy options are unacceptable. Despite these limitations, the use of IL1 inhibitors, in particular canakinumab, seems promising due to the high efficiency of the drug, the ability to use it in patients with comorbid diseases, as well as a favorable effect on the risk of cardiovascular disease.
About the Authors
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522;
Department of Rheumatology, Institute of Professional Education, 8, Trubetskaya St., Build. 2, Moscow 119991
References
1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649-62. doi: 10.1038/nrrheum.2015.91
2. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388:2039-52. doi: 10.1016/S0140-6736(16)00346-9
3. Dalbeth N, House ME, Aati O, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74(5):908-11. doi: 10.1136/annrheumdis-2014-206397
4. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123. doi: 10.1186/s12916-017-0890-9
5. Eliseev MS, Denisov IS, Markelova EI, et al. Independent risk factors for severe cardiovascular complications in men with gout: results of a 7-year prospective study. Terapevticheskii Arkhiv. 2017;87(5):10-9 (In Russ.).
6. Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and metaanalysis. Eur J Prev Cardiol. 2015;22(3):335-43. doi: 10.1177/2047487313514895
7. Chandratre P, Mallen C, Richardson J, Muller S, Hider S, Rome K, Blagojevic-Bucknall M, Roddy E. Health-related quality of life in gout in primary care: Baseline findings from a cohort study. Semin Arthritis Rheum. 2018;48(1):61-9. doi: 10.1016/j.semarthrit.2017.12.005
8. So A, Dumusc A, Nasi S. The role of IL-1 in gout: from bench to bedside. Rheumatology (Oxford). 2018;57(Suppl 1):i12-i19. doi: 10.1093/rheumatology/kex449
9. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639-47. doi: 10.1038/nrrheum.2017.155
10. Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15(1):158. doi: 10.1186/s12916-017-0922-5
11. Desai J, Steiger S, Anders HJ. Molecular Pathophysiology of Gout. Trends Mol Med. 2017;23(8):756-68. doi: 10.1016/j.molmed.2017.06.005
12. Crisan TO, Cleophas MC, Oosting M, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2016;75:755-62. doi: 10.1136/annrheumdis-2014-206564
13. Cleophas MC, Crisan TO, Joosten LA. Factors modulating the inflammatory response in acute gouty arthritis. Curr Opin Rheumatol. 2017;29(2):163-70. doi: 10.1097/BOR.0000000000000366
14. Crisan TO, Netea MG, Joosten LA. Innate immune memory: Implications for host responses to damage-associated molecular patterns. Eur J Immunol. 2016;46(4):817-28. doi: 10.1002/eji.201545497
15. Major TJ, Dalbeth N, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2018;14(6):341-53. doi: 10.1038/s41584-018-0004-x
16. Ter Horst R, Jaeger M, Smeekens SP, et al. Host and environmental factors influencing individual human cytokine responses. Cell. 2016;167:1111-24.e13. doi: 10.1016/j.cell.2016.10.018
17. Joosten LA, Crisan TO, Azam T, et al. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann Rheum Dis. 2016;75:1219-27. doi: 10.1136/annrheumdis-2014-206966
18. Eliseev MS. New international recommendations for the diagnosis and treatment of gout: simple answers to simple questions. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):141-6 (In Russ.). doi: 10.14412/1995-4484-2014-141-146
19. Dalbeth N, Bardin T, Doherty M, et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13(9):561-8. doi: 10.1038/nrrheum.2017.126
20. Eliseev MS. Updated EULAR guidelines for the management of gout. Comments on certain items. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6):600-9 (In Russ.). doi: 10.14412/1995-4484-2017-600-609
21. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. doi: 10.1016/j.amjmed.2010.09.012
22. Schlesinger N. Difficult-to-treat gouty arthritis. A disease warranting better management. Drugs. 2011;71:1413-39. doi: 10.2165/11592290-000000000-00000
23. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765-70. doi: 10.1136/annrheumdis-2012-201687
24. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522-8. doi: 10.1136/annrheumdis-2016-210872
25. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-8. doi: 10.1002/art.24209
26. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378:1200-10. doi: 10.1056/NEJMoa1710895
27. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis2016-209707
28. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70:1264-71. doi: 10.1136/ard.2010.144063
29. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin 1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopuninol is used. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(2):16-22 (In Russ.). doi: 10.14412/1996-7012- 2015-2-16-22
30. So A, De MM, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064-76. doi: 10.1002/art.27600
31. Schlesinger N, De Meulemeester MD, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53. doi: 10.1186/ar3297
32. Schlesinger N, Alten R, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71:1839- 48. doi: 10.1136/annrheumdis-2011-200908
33. Sunkureddi P, Bardin T, Alten R, et al. Efficacy and safety of canakinumab in gouty arthritis patients with chronic kidney disease stage ≥3. Ann Rheum Dis. 2012;71(Suppl 3):447.
34. Alten R, Bloch M, Bardin T. Efficacy and safety of canakinumab vs triamcinolone acetonide in persistent or elderly gouty arthritis patients. Ann Rheum Dis. 2012;71(Suppl 3):700.
35. Marotto D, De Santis A, Chessa D, et al. A Beacon in the Dark: Canakinumab. A New Therapeutic Perspective in Chronic Tophaceous Gout. Rheumatol Ther. 2018;5(1):303-10. doi: 10.1007/s40744-018-0104-8
36. Eliseev MS, Zhelyabin OV, Barskova VG, Nasonov EL. Experience of administration of canakinumab, an interleukin 1β inhibitor, in a patient with chronic tophacaceous gout. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):99-101 (In Russ.). doi: 10.14412/1995-4484-2014-99-101
37. Solomon DH, Glynn RJ, MacFadyen JG, et al. Relationship of Interleukin-1 Blockade With Incident Gout and Serum Uric Acid Levels. Ann Intern Med. 2018;18:1-8. doi: 10.7326/M18-1167
Review
For citations:
Eliseev M.S., Nasonov E.L. Therapy with canakinumab for gout. Rheumatology Science and Practice. 2018;56:41-48. (In Russ.) https://doi.org/10.14412/1995-4484-2018-41-48
Views:
2122
Email this article 